GlassScriptPhysician profile
Luis Sumoza
NPI 1003258583
$16,040.60
in general payments reported to CMS, 2019-2025
75 companies · $4,236 in 2025
The $4,236 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,220 · 2020: $3,133 · 2021: $485 · 2022: $150 · 2023: $591 · 2024: $5,226 · 2025: $4,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,746 · Consulting Fee: $840 · Education: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,746.10 |
| Consulting Fee | $840.00 |
| Education | $466.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,551.05 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Dova Pharmaceuticals | $1,535.03 | 2019-2020 | |
| Janssen Biotech, INC. | $1,300.94 | 2020-2025 | Carvykti, Rybrevant, Tecvayli |
| Merck Sharp & Dohme LLC | $886.40 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $835.62 | 2019-2025 | Calquence, Imfinzi, Tagrisso |
| Pfizer INC. | $757.10 | 2019-2025 | |
| Daiichi Sankyo INC. | $482.94 | 2019-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $418.42 | 2024-2025 | Iclusig, Ninlaro, Alunbrig |
| Pharmaessentia USA Corporation | $381.30 | 2024-2025 | Besremi |
| Incyte Corporation | $328.79 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $320.77 | 2019-2025 | |
| Tempus Ai, INC | $308.53 | 2024-2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $298.87 | 2019-2025 | |
| Genentech USA, INC. | $289.94 | 2019-2025 | Tecentriq, Polivy, Phesgo |
| Celgene Corporation | $283.28 | 2020-2025 | Reblozyl |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $265.82 | 2019-2025 | |
| Amgen INC. | $263.13 | 2019-2021 | |
| Seagen INC. | $256.21 | 2020-2025 | Padcev |
| Lilly USA, LLC | $251.75 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Coherus Oncology, INC. | $249.03 | 2020-2025 | Loqtorzi, Udenyca |
| Pharmacosmos Therapeutics INC. | $199.14 | 2023-2025 | Monoferric, Cosela |
| Adaptive Biotechnologies Corporation | $175.45 | 2022-2024 | Clonoseq |
| Servier Pharmaceuticals LLC | $174.56 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $167.88 | 2019-2023 | Imbruvica |
| Alexion Pharmaceuticals, INC. | $151.90 | 2019-2025 | Ultomiris |
| Abbvie INC. | $149.05 | 2020-2025 | |
| Array Biopharma INC | $143.02 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Emd Serono, INC. | $130.44 | 2019-2024 | Tepmetko, Bavencio |
| Aveo Pharmaceuticals, INC. | $126.63 | 2024 | |
| Karyopharm Therapeutics INC. | $125.89 | 2020-2025 | Xpovio |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Amag Pharmaceuticals, INC. | $124.26 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $99.19 | 2019-2025 | Libtayo, Lynozyfic |
| Dendreon Pharmaceuticals LLC | $97.29 | 2024-2025 | Provenge |
| Rigel Pharmaceuticals, INC. | $97.28 | 2020-2024 | Rezlidhia, Tavalisse |
| Sun Pharmaceutical Industries INC. | $95.25 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $91.32 | 2020-2025 | Onivyde |
| Stemline Therapeutics INC. | $82.88 | 2024-2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $80.76 | 2020-2025 | Pyrukynd |
| Beigene USA, INC. | $78.39 | 2021-2024 | Brukinsa |
| Blueprint Medicines Corporation | $69.68 | 2020-2025 | Ayvakit |
| Azurity Pharmaceuticals, INC. | $67.51 | 2024-2025 | Vivimusta |
| Taiho Oncology, INC. | $65.18 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $62.00 | 2023-2025 | Empaveli |
| Eisai INC. | $61.99 | 2020-2024 | |
| Sobi, INC | $60.36 | 2023-2025 | |
| Mirati Therapeutics, INC. | $58.51 | 2024 | Krazati |
| Myriad Genetic Laboratories, INC. | $54.42 | 2024 | Myrisk |
| Octapharma USA, INC. | $51.04 | 2023 | Octagam Immune Globulin (Human) |
| Kite Pharma, INC. | $50.55 | 2021-2023 | Yescarta |
| Deciphera Pharmaceuticals INC. | $49.89 | 2023-2024 | Qinlock |
| Legend Biotech USA INC. | $48.61 | 2024-2025 | Carvykti |
| Tersera Therapeutics LLC | $47.70 | 2019-2024 | Quzyttir |
| Astellas Pharma US INC | $40.51 | 2024 | Padcev |
| Springworks Therapeutics, INC. | $39.51 | 2024-2025 | Gomekli, Ogsiveo |
| Beone Medicines USA, INC. | $37.80 | 2025 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $37.32 | 2021-2025 | |
| Puma Biotechnology, INC. | $36.01 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $28.02 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $27.54 | 2025 | Enjaymo |
| Jazz Pharmaceuticals INC. | $26.36 | 2025 | |
| Menarini Silicon Biosystems, INC. | $24.64 | 2025 | |
| Iovance Biotherapeutics, INC. | $23.65 | 2025 | Amtagvi |
| Progenics Pharmaceuticals, INC. | $22.20 | 2025 | |
| Biocon Biologics INC | $21.93 | 2025 | Ogivri |
| Spectrum Pharmaceuticals INC. | $21.77 | 2025 | Rolvedon |
| G1 Therapeutics, INC. | $20.00 | 2023 | Cosela |
| Caris Mpi, INC. | $18.41 | 2025 | Mi Cancer Seek |
| Amneal Pharmaceuticals LLC | $17.27 | 2025 | Alymsys |
| Teva Pharmaceuticals USA, INC. | $15.43 | 2021 | |
| Clovis Oncology, INC. | $14.73 | 2019 | |
| Novocure INC. | $14.35 | 2025 | Optune Lua (Novottf-200t) |
| Verastem, INC. | $13.42 | 2019 | |
| Pharmaand Gmbh | $11.79 | 2025 | Rubraca |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Sumoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.